Welcome back, warriors! In this week’s special episode of Peptide of the Week, JD Denham and William T. Haas are joined by peptide researcher and clinical expert Paul Bakhtiar to break down the biggest developments shaking up the entire peptide industry.

From FDA crackdowns to the future of GLP-1s like Retatrutide, this episode gives you the real insider breakdown of what’s happening, why it matters, and what you should do right now if you’re using or selling peptides.

We cover:

⚠️ Retatrutide: What’s changing & when

– Big Pharma is moving fast to monopolize Retatrutide via FDA approval

– Once approved, it will no longer be available through research-use sites

– Access will be limited to prescription only via 503A/503B pharmacies & telehealth

– Expect price increases of 50–100% compared to current availability

💉 What does this mean for GLP-1 users?

– Stock up NOW if you’re using Retatrutide (powder can last 2+ years unreconstituted)

– Semaglutide & Tirzepatide may still be available for a time, but not forever

– New rules are expected by Q1 2026, if not sooner

– Telehealth will become the main legal route for GLP-1s and other “controlled” peptides

📉 What about other peptides (BPC-157, TB-500, MOTC, etc.)?

– The FDA is quietly reclassifying peptides as “biologics” to open them up for patents

– 25–40 peptides are expected to become FDA approved in the next 12–18 months

– Research-use availability will continue for now, but eventually move to doctor-prescribed only

💣 Why this proves peptides are the real deal

– Peptides work that’s why Big Pharma is jumping in

– The move to medicalize & retailize peptides is proof they’re not fringe they’re the future

– Good news: this also removes bad actors & fake COAs from the market

📌 Whether you’re a casual user or deep in the industry this episode is a must-listen for truth over headlines and clarity over fear.

💬 Got questions? Drop them in the comments and we’ll keep unpacking this in future episodes.

📺 Subscribe for weekly deep dives into the truth about performance, healing, and longevity. No fluff. No fear. Just facts.

Stay Connected & Follow Us!

JD's Instagram: https://www.instagram.com/jd_denham_fit

JD's Facebook: https://www.facebook.com/people/JD-Denham/61563578940850/

Wills Instagram: https://www.instagram.com/williamthaas/

Paul Bakhtiar's Instagram: https://www.instagram.com/paulbakhtiar/

Peptide of the Week: Industry Update – Retatrutide, GLP-1s & FDA Moves Explained

Peptide of the Week | Weight Loss, Health & Wellness

Peptide of the Week: Industry Update – Retatrutide, GLP-1s & FDA Moves Explained